...
首页> 外文期刊>Journal of Translational Medicine >Epidermal growth factor receptor and epididymis invasion as prognostic biomarkers in clinical stage I testicular germ cell tumours
【24h】

Epidermal growth factor receptor and epididymis invasion as prognostic biomarkers in clinical stage I testicular germ cell tumours

机译:表皮生长因子受体和附睾侵袭是临床I期睾丸生殖细胞肿瘤的预后生物标志物

获取原文
           

摘要

Background Inguinal orchiectomy is curative in 70–80% of clinical stage I testicular germ cell tumours (CS I TGCT). The identification of patients who are at low risk of relapse is critical to avoid unnecessary treatment. The aim of this study is to explore EGFR, hMLH-1/hMSH-2 and microsatellite instability (MSI) as potential prognostic factors of recurrence in CS I TGCT. Methods Fifty-six CS I TGCT patients who underwent inguinal orchiectomy were included in this study. We analysed the relationship between clinicopathological and molecular factors with survival. Analysis of hMLH1, hMSH2 and EGFR expression was carried out by immunohistochemistry. Methylation status of the hMLH1 promoter was determined by pyrosequencing analysis in selected cases. EGFR exons 19, 20, 21 were analysed by PCR labeled-fragments and MSI status was determined using standard Multiplex MSI assays. Results Classical pathological factors such as lymphovascular invasion, high percentage of embryonal carcinoma, rete testis invasion or tumour size ≥4?cm showed a significant relationship with a higher risk of relapse. Additionally, it was found that an epididymis invasion proved to be a significant independent poor prognostic factor of recurrence (p?=?0.001). hMLH1 or hMSH2 expression showed no significant association with risk of relapse and no MSI was found. EGFR expression was observed in 30.4% of samples and its expression was associated with higher risk of relapse (HR 3.5; 95% CI 1.3–9.8; p?=?0.016). None of the cases presented EGFR kinase domain mutations. Conclusions Epididymis invasion and EGFR expression, but not hMLH-1/hMSH-2 or MSI, could be potentially useful as new prognostic factors of recurrence for CS I TGCT.
机译:背景腹股沟睾丸切除术可治愈70-80%的临床I期睾丸生殖细胞肿瘤(CS I TGCT)。识别低复发风险的患者对于避免不必要的治疗至关重要。这项研究的目的是探讨EGFR,hMLH-1 / hMSH-2和微卫星不稳定性(MSI)作为CS I TGCT复发的潜在预后因素。方法包括56例行腹股沟睾丸切除术的CS I TGCT患者。我们分析了临床病理和分子因素与生存之间的关系。通过免疫组织化学分析hMLH1,hMSH2和EGFR的表达。在某些情况下,通过焦磷酸测序分析确定了hMLH1启动子的甲基化状态。通过PCR标记片段分析EGFR外显子19、20、21,并使用标准Multiplex MSI测定法确定MSI状态。结果淋巴管浸润,胚胎癌发生率高,睾丸网状浸润或肿瘤大小≥4?cm等经典病理因素与复发风险较高有显着相关性。另外,发现附睾浸润被证明是复发的重要的独立的不良预后因素(p≤0.001)。 hMLH1或hMSH2表达与复发风险无显着关联,也未发现MSI。在30.4%的样本中观察到EGFR表达,其表达与更高的复发风险相关(HR 3.5; 95%CI 1.3-9.8; p?=?0.016)。没有一个病例表现出EGFR激酶结构域突变。结论附睾侵袭和EGFR表达而非hMLH-1 / hMSH-2或MSI可能作为CS I TGCT复发的新预后因素。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号